A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Single Oral Doses of SEP-225289 in Subjects 6 to 17 Years of Age With Attention Deficit Hyperactivity Disorder
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2015
Price : $35 *
At a glance
- Drugs Dasotraline (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sunovion Pharmaceuticals
- 30 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Jul 2014 New trial record
- 23 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.